LAURA KERSEY: Open Payments
NPI 1588226104 · DES MOINES, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,229 in 55 payments from 10 companies in 2025. Trend: 2023 $3,925 · 2024 $810 · 2025 $1,229
Food & beverage: $1,164Education: $66
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 22 | $469 |
| AstraZeneca Pharmaceuticals LP | 18 | $350 |
| GlaxoSmithKline, LLC. | 4 | $164 |
| SANOFI-AVENTIS U.S. LLC | 1 | $57 |
| Novartis Pharmaceuticals Corporation | 3 | $57 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $47 |
| CSL Behring | 1 | $33 |
| Genentech USA, Inc. | 1 | $20 |
| Jubilant HollisterStier LLC | 1 | $18 |
| Galderma Laboratories, L.P. | 1 | $15 |
Products named: DUPIXENT, FASENRA, NUCALA, WAYRILZ, AIRSUPRA, XOLAIR, TEZSPIRE, NEFFY.
Industry payments across IA — which companies pay providers there.
